Soluble mTOR complexes and modulators thereof
Abstract
The present invention relates to small molecule modulators of mTORC1 and mTORC2, syntheses thereof, and intermediates thereto. Such small molecule modulators are useful in the treatment of proliferative diseases (e.g., benign neoplasms, cancers, inflammatory diseases, autoimmune diseases, diabetic retinopathy) and metabolic diseases. Novel small molecules are provided that inhibit one or more of mTORC1, mTORC2, and PI3K-related proteins. Novel methods of providing soluble mTORC1 and mTORC2 complexes are discussed, as well as methods of using the soluble complexes in a high-throughput manner to screen for inhibitory compounds.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A compound selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
2. The compound according to claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable excipient.
5. A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable excipient.
6. A pharmaceutical composition comprising a compound according to claim 3 and a pharmaceutically acceptable excipient.Join the waitlist — get patent alerts
Track US8889706B2 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.